ArticleFrontiers in medicine2026
Metamizole-induced agranulocytosis from a German intensive care perspective.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Metamizole (dipyrone) is a non-opioid analgesic and antipyretic widely used in Germany, with prescriptions having increased more than tenfold since 1997. Despite its popularity, metamizole remains controversial due to the risk of agranulocytosis-a potentially life-threatening adverse reaction that can occur independently of dose or duration of therapy. This study aimed to describe severe cases of metamizole-induced agranulocytosis requiring intensive care treatment and to contextualize them within current consumption data. Methods: A retrospective analysis was conducted of all patients admitted to the interdisciplinary medical intensive care units of a tertiary university hospital in southern Germany between April 2022 and April 2025 due to metamizole-associated agranulocytosis. Demographic, clinical, and laboratory data were collected. Bone marrow examinations, microbiological findings, treatment regimens, and outcomes were analyzed descriptively. Results: Seven patients required intensive care for metamizole-induced agranulocytosis. All presented with profound neutropenia and severe infections. Two patients died from multiorgan failure despite maximal supportive care. The five survivors experienced prolonged ICU stays (11-60 days) with complications including septic shock, acute respiratory distress syndrome, and renal failure requiring dialysis. None of the patients had pre-existing hematologic disorders or immunosuppression. Conclusion: Metamizole-induced agranulocytosis is a rare but potentially severe adverse reaction. Even though its absolute incidence is low relative to the widespread use of metamizole, affected patients may experience life-threatening complications. Awareness of this risk, combined with careful benefit-risk assessment and consideration of alternative analgesics, remains essential for safe and rational use of metamizole in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.